Mesoblast Limited

1.10 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Mesoblast Limited stock is down -15.38% since 30 days ago. The next earnings date is Dec 19, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 2 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
10 Nov 18:35 16 Jan, 2026 2.50 CALL 440 1110
13 Nov 16:56 16 Jan, 2026 2.50 CALL 460 1551

About Mesoblast Limited

Mesoblast Limited offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection. The company has strategic partnerships with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd. and Grünenthal.